GlassScriptPhysician profile
Cezina Y Rocha
NPI 1861586356
$5,650.32
in general payments reported to CMS, 2019-2025
27 companies · $24.48 in 2025
The $24.48 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $398 · 2021: $872 · 2022: $1,581 · 2023: $932 · 2024: $650 · 2025: $24.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,508.32 | 2019-2024 | Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $887.14 | 2019-2024 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $328.42 | 2019-2024 | Entyvio |
| Cook Medical LLC | $236.36 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $224.48 | 2019 | |
| Intercept Pharmaceuticals, INC. | $190.82 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $177.90 | 2024-2025 | Voquezna |
| Celgene Corporation | $122.84 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.44 | 2019 | |
| Glaxosmithkline, LLC. | $118.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.92 | 2022 | |
| Ambu INC. | $89.32 | 2020 | |
| Redhill Biopharma INC. | $70.45 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $60.16 | 2022 | |
| Edwards Lifesciences Corporation | $57.60 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56.77 | 2021 | |
| Merck Sharp & Dohme LLC | $50.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.72 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $46.25 | 2021 | |
| Braintree Laboratories, INC. | $31.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $23.12 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.80 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $17.61 | 2019 | |
| Boston Scientific Corporation | $17.21 | 2024 | Exalt Model D |
| Daiichi Sankyo INC. | $16.20 | 2021 | |
| Olympus America INC. | $11.27 | 2019 | |
| Janssen Biotech, INC. | $4.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cezina Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.